

12-8080: Anti-Human IL-2R alpha (CD25) (Basiliximab) - APC

Clonality :	Monoclonal
Clone Name :	Hu107
Application :	FACS
Alternative Name :	IL-2-RA; IL2-RA; TAC antigen; p55; CD25
Isotype :	Human IgG1k
Immunogen Information :	Human CD25

Description

Expression Host : HEK-293

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Basiliximab. Basiliximab recognizes human CD25. This product is for research use only.

CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Ralpha. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects.

Product Info

Amount :	50 µg Concentration : 0.2 mg/ml
Content :	This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage condition :	This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.

Application Note

The suggested concentration for Basiliximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.